{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:23:23Z","timestamp":1789025003883,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11523-024-01119-z","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T18:39:00Z","timestamp":1734460740000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-886X","authenticated-orcid":false,"given":"David J.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain C.","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"issue":"6","key":"1119_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"1119_CR2","doi-asserted-by":"crossref","unstructured":"Downes MR. Invasive Urothelial Carcinoma: Subtypes and Divergent Differentiation. In: Barber N, Ali A, eds. Urologic Cancers. Exon Publications; 2022. Accessed August 14, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585978\/","DOI":"10.36255\/exon-publications-urologic-cancers-urothelial-carcinoma"},{"issue":"1","key":"1119_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2018;73(1):111\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036.","journal-title":"Eur Urol"},{"key":"1119_CR4","doi-asserted-by":"publisher","unstructured":"Hepp Z, Shah SN, Smoyer K, Vadagam P. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. J Manag Care Spec Pharm. 2021;27(2):https:\/\/doi.org\/10.18553\/jmcp.2020.20285. https:\/\/doi.org\/10.18553\/jmcp.2020.20285","DOI":"10.18553\/jmcp.2020.20285 10.18553\/jmcp.2020.20285"},{"issue":"2","key":"1119_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033.","journal-title":"Eur Urol"},{"issue":"7","key":"1119_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer","year":"1992","unstructured":"Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066\u201373. https:\/\/doi.org\/10.1200\/JCO.1992.10.7.1066.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1119_CR7","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1119_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"19","key":"1119_CR9","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"issue":"3","key":"1119_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.euo.2024.02.010","volume":"7","author":"DJ Benjamin","year":"2024","unstructured":"Benjamin DJ, Rezazadeh Kalebasty A, Prasad V. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma? Eur Urol Oncol. 2024;7(3):313\u20135. https:\/\/doi.org\/10.1016\/j.euo.2024.02.010.","journal-title":"Eur Urol Oncol."},{"issue":"13","key":"1119_CR11","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3390\/cancers16132398","volume":"16","author":"VK Srinivasalu","year":"2024","unstructured":"Srinivasalu VK, Robbrecht D. Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions. Cancers. 2024;16(13):2398. https:\/\/doi.org\/10.3390\/cancers16132398.","journal-title":"Cancers"},{"key":"1119_CR12","unstructured":"Gilead Provides Update on U.S. Indication for Trodelvy\u00ae in Metastatic Urothelial Cancer. Accessed October 30, 2024. https:\/\/www.gilead.com\/company\/company-statements\/2024\/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer"},{"issue":"9","key":"1119_CR13","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A. Erdafitinib: First Global Approval. Drugs. 2019;79(9):1017\u201321. https:\/\/doi.org\/10.1007\/s40265-019-01142-9.","journal-title":"Drugs"},{"issue":"19","key":"1119_CR14","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2016-0042","volume":"12","author":"E di Martino","year":"2016","unstructured":"di Martino E, Tomlinson DC, Williams SV, Knowles MA. A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol. 2016;12(19):2243\u201363. https:\/\/doi.org\/10.2217\/fon-2016-0042.","journal-title":"Future Oncol"},{"issue":"1","key":"1119_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/path.2207","volume":"213","author":"DC Tomlinson","year":"2007","unstructured":"Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213(1):91\u20138. https:\/\/doi.org\/10.1002\/path.2207.","journal-title":"J Pathol"},{"key":"1119_CR16","doi-asserted-by":"publisher","unstructured":"Liu Q, Huang J, Yan W, Liu Z, Liu S, Fang W. FGFR families: biological functions and therapeutic interventions in tumors. MedComm (2020). 2023;4(5):e367. https:\/\/doi.org\/10.1002\/mco2.367","DOI":"10.1002\/mco2.367"},{"issue":"1","key":"1119_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, et al. FGF\/FGFR signaling in health and disease. Sig Transduct Target Ther. 2020;5(1):1\u201338. https:\/\/doi.org\/10.1038\/s41392-020-00222-7.","journal-title":"Sig Transduct Target Ther."},{"issue":"7","key":"1119_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","volume":"20","author":"S Du","year":"2023","unstructured":"Du S, Zhang Y, Xu J. Current progress in cancer treatment by targeting FGFR signaling. Cancer Biol Med. 2023;20(7):490\u20139. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0137.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"1119_CR19","first-page":"71","volume":"9","author":"PY d\u2019Avis","year":"1998","unstructured":"d\u2019Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ. 1998;9(1):71\u20138.","journal-title":"Cell Growth Differ"},{"issue":"4","key":"1119_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/hmg\/dds486","volume":"22","author":"SV Williams","year":"2013","unstructured":"Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22(4):795\u2013803. https:\/\/doi.org\/10.1093\/hmg\/dds486.","journal-title":"Hum Mol Genet"},{"key":"1119_CR21","doi-asserted-by":"publisher","unstructured":"Ascione CM, Napolitano F, Esposito D, et al. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treatment Reviews. 2023;115. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102530","DOI":"10.1016\/j.ctrv.2023.102530"},{"issue":"16","key":"1119_CR22","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","volume":"25","author":"R Bahleda","year":"2019","unstructured":"Bahleda R, Italiano A, Hierro C, et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res. 2019;25(16):4888\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3334.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1119_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1817323.","journal-title":"N Engl J Med"},{"issue":"21","key":"1119_CR24","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023;389(21):1961\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2308849.","journal-title":"N Engl J Med"},{"issue":"1","key":"1119_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clgc.2021.10.004","volume":"20","author":"Y Lyou","year":"2022","unstructured":"Lyou Y, Rosenberg JE, Hoffman-Censits J, et al. Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2022;20(1):35\u201342. https:\/\/doi.org\/10.1016\/j.clgc.2021.10.004.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"1119_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/JCO.21.02303","volume":"41","author":"CN Sternberg","year":"2023","unstructured":"Sternberg CN, Petrylak DP, Bellmunt J, et al. FORT-1: Phase II\/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1\/3 mRNA Expression. J Clin Oncol. 2023;41(3):629\u201339. https:\/\/doi.org\/10.1200\/JCO.21.02303.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1119_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2023.10.794","volume":"35","author":"A Necchi","year":"2024","unstructured":"Necchi A, Pouessel D, Leibowitz R, et al. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF\/FGFR genomic alterations: final results from FIGHT-201. Ann Oncol. 2024;35(2):200\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.794.","journal-title":"Ann Oncol"},{"key":"1119_CR28","doi-asserted-by":"publisher","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","volume":"34","author":"A Vilaseca","year":"2023","unstructured":"Vilaseca A, Jayram G, Raventos C, et al. LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt). Ann Oncol. 2023;34:S1343. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.110.","journal-title":"Ann Oncol"},{"issue":"2","key":"1119_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/cancers16020335","volume":"16","author":"DM Patel","year":"2024","unstructured":"Patel DM, Mateen R, Qaddour N, et al. A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines. Cancers. 2024;16(2):335. https:\/\/doi.org\/10.3390\/cancers16020335.","journal-title":"Cancers"},{"issue":"7492","key":"1119_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322. https:\/\/doi.org\/10.1038\/nature12965.","journal-title":"Nature"},{"issue":"3","key":"1119_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","volume":"72","author":"W Choi","year":"2017","unstructured":"Choi W, Ochoa A, McConkey DJ, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol. 2017;72(3):354\u201365. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.010.","journal-title":"Eur Urol"},{"issue":"10031","key":"1119_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4.","journal-title":"Lancet"},{"issue":"3","key":"1119_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30065-7.","journal-title":"Lancet Oncol"},{"key":"1119_CR34","doi-asserted-by":"publisher","first-page":"117955492211262","DOI":"10.1177\/11795549221126252","volume":"16","author":"DJ Benjamin","year":"2022","unstructured":"Benjamin DJ, Mar N, Rezazadeh KA. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. Clin Med Insights Oncol. 2022;16:11795549221126252. https:\/\/doi.org\/10.1177\/11795549221126252.","journal-title":"Clin Med Insights Oncol."},{"issue":"9","key":"1119_CR35","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","volume":"7","author":"S Palakurthi","year":"2019","unstructured":"Palakurthi S, Kuraguchi M, Zacharek SJ, et al. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. Cancer Immunol Res. 2019;7(9):1457\u201371. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0595.","journal-title":"Cancer Immunol Res"},{"key":"1119_CR36","doi-asserted-by":"publisher","unstructured":"Siefker-Radtke AO, Powles T, Moreno V, et al. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study. JCO. 2023;41(16_suppl):4504-4504. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4504","DOI":"10.1200\/JCO.2023.41.16_suppl.4504"},{"key":"1119_CR37","doi-asserted-by":"publisher","first-page":"S1136","DOI":"10.1016\/j.annonc.2024.08.2050","volume":"35","author":"VS Koshkin","year":"2024","unstructured":"Koshkin VS, Barthelemy P, Gravis G, et al. 1965MO Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced\/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety. Ann Oncol. 2024;35:S1136\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2050.","journal-title":"Ann Oncol"},{"key":"1119_CR38","doi-asserted-by":"publisher","unstructured":"Necchi A, Ramlau R, Falc\u00f3n Gonz\u00e1lez A, et al. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectrum. 2024;8(3):pkae030. https:\/\/doi.org\/10.1093\/jncics\/pkae030","DOI":"10.1093\/jncics\/pkae030"},{"issue":"17","key":"1119_CR39","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/onc.2014.161","volume":"34","author":"J Wang","year":"2015","unstructured":"Wang J, Mikse O, Liao RG, et al. Ligand associated ERBB2\/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells. Oncogene. 2015;34(17):2167\u201377. https:\/\/doi.org\/10.1038\/onc.2014.161.","journal-title":"Oncogene"},{"issue":"1","key":"1119_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Sig Transduct Target Ther. 2022;7(1):1\u201336. https:\/\/doi.org\/10.1038\/s41392-022-01168-8.","journal-title":"Sig Transduct Target Ther."},{"issue":"25","key":"1119_CR41","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/onc.2012.319","volume":"32","author":"V Chell","year":"2013","unstructured":"Chell V, Balmanno K, Little AS, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 2013;32(25):3059\u201370. https:\/\/doi.org\/10.1038\/onc.2012.319.","journal-title":"Oncogene"},{"issue":"7","key":"1119_CR42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","volume":"8","author":"SK Pal","year":"2018","unstructured":"Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018;8(7):812\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0229.","journal-title":"Cancer Discov"},{"issue":"22","key":"1119_CR43","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","volume":"29","author":"BJ Guercio","year":"2023","unstructured":"Guercio BJ, Sarfaty M, Teo MY, et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin Cancer Res. 2023;29(22):4586\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1283.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1119_CR44","doi-asserted-by":"publisher","first-page":"24252","DOI":"10.18632\/oncotarget.8132","volume":"7","author":"H Patani","year":"2016","unstructured":"Patani H, Bunney TD, Thiyagarajan N, et al. Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget. 2016;7(17):24252\u201368. https:\/\/doi.org\/10.18632\/oncotarget.8132.","journal-title":"Oncotarget"},{"issue":"9","key":"1119_CR45","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","volume":"13","author":"F Facchinetti","year":"2023","unstructured":"Facchinetti F, Hollebecque A, Braye F, et al. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer. Cancer Discov. 2023;13(9):1998\u20132011. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1441.","journal-title":"Cancer Discov"},{"issue":"4","key":"1119_CR46","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/cam4.262","volume":"3","author":"EA Guancial","year":"2014","unstructured":"Guancial EA, Werner L, Bellmunt J, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014;3(4):835\u201344. https:\/\/doi.org\/10.1002\/cam4.262.","journal-title":"Cancer Med"},{"key":"1119_CR47","doi-asserted-by":"publisher","unstructured":"Clinton TN, Chen Z, Wise H, et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Reports. 2022;41(12). https:\/\/doi.org\/10.1016\/j.celrep.2022.111859","DOI":"10.1016\/j.celrep.2022.111859"},{"key":"1119_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.12.019","volume":"50","author":"AO Siefker-Radtke","year":"2023","unstructured":"Siefker-Radtke AO, Necchi A, Park SH, et al. Management of Fibroblast Growth Factor Inhibitor Treatment\u2013emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. European Urology Open Science. 2023;50:1\u20139. https:\/\/doi.org\/10.1016\/j.euros.2022.12.019.","journal-title":"European Urology Open Science."},{"issue":"4","key":"1119_CR49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, et al. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol. 2023;9(4):465\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7826.","journal-title":"JAMA Oncol"},{"key":"1119_CR50","doi-asserted-by":"publisher","unstructured":"Benjamin DJ, Lythgoe MP, Rezazadeh A. Financial Toxicity from Newly Approved Second-\/Third-Line Agents in Metastatic Urothelial Carcinoma. BJU Int. Published online March 6, 2023. https:\/\/doi.org\/10.1111\/bju.16003","DOI":"10.1111\/bju.16003"},{"key":"1119_CR51","doi-asserted-by":"publisher","unstructured":"de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Network Open. 2019;2(11):e1916091. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16091","DOI":"10.1001\/jamanetworkopen.2019.16091"},{"issue":"1","key":"1119_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Sig Transduct Target Ther. 2022;7(1):1\u201325. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Sig Transduct Target Ther."},{"issue":"6","key":"1119_CR53","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cncr.34057","volume":"128","author":"VS Koshkin","year":"2022","unstructured":"Koshkin VS, Henderson N, James M, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022;128(6):1194\u2013205. https:\/\/doi.org\/10.1002\/cncr.34057.","journal-title":"Cancer"},{"issue":"6","key":"1119_CR54","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","volume":"39","author":"C Kollmannsberger","year":"2021","unstructured":"Kollmannsberger C, Britten CD, Olszanski AJ, et al. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. Invest New Drugs. 2021;39(6):1613\u201323. https:\/\/doi.org\/10.1007\/s10637-021-01146-x.","journal-title":"Invest New Drugs"},{"key":"1119_CR55","doi-asserted-by":"publisher","unstructured":"Min B, Shi L, Kim HJ, et al. Abstract 2634: AMB302\/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion. Cancer Research. 2023;83(7_Supplement):2634. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2634","DOI":"10.1158\/1538-7445.AM2023-2634"},{"key":"1119_CR56","doi-asserted-by":"publisher","unstructured":"Min B, Lee S, Jung W, et al. Abstract 3123: Preclinical characterization of AMB302\/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor against diverse FGFR3 overexpression or alteration. Cancer Research. 2024;84(6_Supplement):3123. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-3123","DOI":"10.1158\/1538-7445.AM2024-3123"},{"issue":"2","key":"1119_CR57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/bco2.125","volume":"3","author":"E Adib","year":"2021","unstructured":"Adib E, El-Zarif T, Jain RK, et al. FGFR2\/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. BJUI Compass. 2021;3(2):169\u201372. https:\/\/doi.org\/10.1002\/bco2.125.","journal-title":"BJUI Compass."},{"issue":"6","key":"1119_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16183","volume":"5","author":"MP Lythgoe","year":"2022","unstructured":"Lythgoe MP, Desai A, Gyawali B, et al. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010\u20132019. JAMA Netw Open. 2022;5(6): e2216183. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.16183.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1119_CR59","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaoncol.2022.1167","volume":"8","author":"V Nimgaonkar","year":"2022","unstructured":"Nimgaonkar V, Hubbard RA, Carpenter EL, Mamtani R. Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy. JAMA Oncol. 2022;8(7):1070\u20132. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1167.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1119_CR60","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. 2023;24(11):9674. https:\/\/doi.org\/10.3390\/ijms24119674.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1119_CR61","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","volume":"78","author":"S Garc\u00eda-Alonso","year":"2018","unstructured":"Garc\u00eda-Alonso S, Oca\u00f1a A, Pandiella A. Resistance to Antibody-Drug Conjugates. Can Res. 2018;78(9):2159\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3671.","journal-title":"Can Res"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01119-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01119-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01119-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T14:22:24Z","timestamp":1737814944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01119-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01119-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support and sponsorship"}},{"value":"David J. Benjamin has the following disclosures: Consulting\/advisory role: AIMED BIO, Astellas, AVEO Oncology, Bayer, Eisai, EMD Serono, Exelixis, and Seagen. Speakers\u2019 bureau: Merck. Travel and accommodations: DAVA Oncology, Merck, and Seagen. Alain C. Mita has the following disclosures: Speakers\u2019 bureau: Genentech. Alain C. Mita is an editorial board member of Targeted Oncology. Alain C. Mita was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"DJB\u2014conceptualization, investigation, writing\u2014original draft, writing\u2014review and editing; ACM\u2014writing\u2014original draft, writing\u2014review and editing, supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}